GlassScriptPhysician profile
Michelle Staley
NPI 1417370487
$1,156.11
in general payments reported to CMS, 2019-2025
13 companies · $1,156 in 2025
The $1,156 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $254.53 | 2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $208.58 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $119.85 | 2025 | Rexulti |
| Abbvie INC. | $111.02 | 2025 | |
| Lundbeck LLC | $102.33 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $101.14 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $66.95 | 2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $52.55 | 2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $43.74 | 2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $36.00 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $21.62 | 2025 | Zurzuvae |
| Teva Pharmaceuticals USA, INC. | $19.53 | 2025 | Austedo Xr |
| Corium, LLC | $18.27 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Staley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.